Cancer: is a disease in which abnormal cells divide uncontrollably and destroy body tissue. Cancerous tumors are malignant, which means they can spread into, or invade, nearby tissues.
Survival rates for patients with high grade serous carcinoma of the ovary (HGSC) have stagnated for the past fifty years. Despite the presence of tumor mutations and infiltration of immune c...
Latest advancements in limited sample analysis will be presented. The webinar will focus specifically on single-cell proteomics and deep visual proteomics and how latest innovations in mass...
Explore the latest developments in cancer organoid (tumoroid) technology and the promising implications for drug screening during this two-part webinar. In the first half, Colin Paul will di...
In light of the numerous US FDA-approved humanized monoclonal antibodies (mAbs) for cancer immunotherapy, it is surprising that the advancement of B-cell epitope vaccines designed to elicit...
Cell-based therapeutics show immense promise in treating a variety of currently incurable diseases due to their potent mechanisms. However, despite recent successes, challenges persist in ma...
The recognition of mRNA molecules as a transformative class of therapeutic drugs has soared, particularly with the development of COVID 19 mRNA vaccines. The cancer treatment landscape is si...
Chimeric antigen receptor (CAR) T-cell therapy shows significant potential in treating various human cancers. Unfortunately, researchers have faced difficulty in adapting this therapy to tar...
Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel therapeutic option for cancer patients in recent years. Despite its success, this approach faces acknowledged limitation...
Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieve a durable complete response. Furthermore,...
Nanovials are emerging as an accessible platform for performing single-cell functional screening leveraging standard instrumentation, such as flow cytometers and microfluidic single-cell seq...
Chimeric antigen receptor (CAR) T-cell therapy has been extremely successful in treating relapsed/refractory B-cell malignancies, with six CAR T-cell products now FDA approved. Unfortunately...
In the field of tumor immunotherapy, cancer vaccines are designed to help the immune system recognize and attack cancer cells. More efforts are needed to identify neoantigens, develop combin...
Understanding the spatial organization of the immune response within tumors is crucial for developing effective cancer immunotherapies. In this seminar, we delve into the interactions betwee...
Throughout history, various approaches including surgery, radiation therapy, chemotherapy, and targeted therapy have been employed in the fight against cancer. In the 2010s, the emergence of...
Adoptive cell therapy (ACT) is an immunotherapy that employs living immune cells to target and destroy cancer cells. However, the inhibitory tumor microenvironment features several obstacles...
Brain cancer research stands to benefit from the perspectives, tools, and methodologies of non-traditional fields, such as mechanical engineering. Here, I will discuss our engineering-based...
Ovarian Cancer is the 8th most common cancer in the world, and Europe has the highest rates of ovarian cancer in the world. Although the cancer antigen 125 (CA 125) assay has been used for m...
The Comprehensive Genomic Profiling (CGP) ctDNA (circulating tumor DNA) panel generates complex biomarkers, e.g., tumor mutational burden and microsatellite stability status along with mutat...
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
B cell responses within pancreatic ductal adenocarcinoma (PDAC) tumors are associated with improved patient outcomes, yet the specific triggering antigens remain largely unknown. In this web...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Nanovials are emerging as an accessible platform for performing single-cell functional screening leveraging standard instrumentation, such as flow cytometers and microfluidic single-cell seq...
Survival rates for patients with high grade serous carcinoma of the ovary (HGSC) have stagnated for the past fifty years. Despite the presence of tumor mutations and infiltration of immune c...
Latest advancements in limited sample analysis will be presented. The webinar will focus specifically on single-cell proteomics and deep visual proteomics and how latest innovations in mass...
Explore the latest developments in cancer organoid (tumoroid) technology and the promising implications for drug screening during this two-part webinar. In the first half, Colin Paul will di...
In light of the numerous US FDA-approved humanized monoclonal antibodies (mAbs) for cancer immunotherapy, it is surprising that the advancement of B-cell epitope vaccines designed to elicit...
Cell-based therapeutics show immense promise in treating a variety of currently incurable diseases due to their potent mechanisms. However, despite recent successes, challenges persist in ma...
The recognition of mRNA molecules as a transformative class of therapeutic drugs has soared, particularly with the development of COVID 19 mRNA vaccines. The cancer treatment landscape is si...
Chimeric antigen receptor (CAR) T-cell therapy shows significant potential in treating various human cancers. Unfortunately, researchers have faced difficulty in adapting this therapy to tar...
Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel therapeutic option for cancer patients in recent years. Despite its success, this approach faces acknowledged limitation...
Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieve a durable complete response. Furthermore,...
Nanovials are emerging as an accessible platform for performing single-cell functional screening leveraging standard instrumentation, such as flow cytometers and microfluidic single-cell seq...
Chimeric antigen receptor (CAR) T-cell therapy has been extremely successful in treating relapsed/refractory B-cell malignancies, with six CAR T-cell products now FDA approved. Unfortunately...
In the field of tumor immunotherapy, cancer vaccines are designed to help the immune system recognize and attack cancer cells. More efforts are needed to identify neoantigens, develop combin...
Understanding the spatial organization of the immune response within tumors is crucial for developing effective cancer immunotherapies. In this seminar, we delve into the interactions betwee...
Throughout history, various approaches including surgery, radiation therapy, chemotherapy, and targeted therapy have been employed in the fight against cancer. In the 2010s, the emergence of...
Adoptive cell therapy (ACT) is an immunotherapy that employs living immune cells to target and destroy cancer cells. However, the inhibitory tumor microenvironment features several obstacles...
Brain cancer research stands to benefit from the perspectives, tools, and methodologies of non-traditional fields, such as mechanical engineering. Here, I will discuss our engineering-based...
Ovarian Cancer is the 8th most common cancer in the world, and Europe has the highest rates of ovarian cancer in the world. Although the cancer antigen 125 (CA 125) assay has been used for m...
The Comprehensive Genomic Profiling (CGP) ctDNA (circulating tumor DNA) panel generates complex biomarkers, e.g., tumor mutational burden and microsatellite stability status along with mutat...
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
B cell responses within pancreatic ductal adenocarcinoma (PDAC) tumors are associated with improved patient outcomes, yet the specific triggering antigens remain largely unknown. In this web...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Nanovials are emerging as an accessible platform for performing single-cell functional screening leveraging standard instrumentation, such as flow cytometers and microfluidic single-cell seq...
Follow
